The Index · Healthcare

India AI-Native Index · Edition one · Public evidence only

Max Healthcare

Scored on public evidence published between February 2025 and August 2026, reviewed through 30 August 2026, under the Edition 1 locked rule set (ANS-100/P v2.1, 1-floor on every question). Provisional result and evidence annexure sent to the company fourteen days before publication.

38.1Score out of 100
AI AssistedBand · 21–40 · boundary
BConfidence · 5 of 8 evidence categories
NoneCeilings triggered

Bands are calibrated thresholds on the published scale, not ranks.

What this assessment is, and is not

The Index measures what a company has placed on the public record about its use of AI, within the evidence window, against a published rubric. It does not measure business performance, product quality, safety, customer outcomes, or the adequacy of internal controls. A low score on any question means that, in the public sources listed below, reviewed through the cut-off date, disclosure sufficient to satisfy the published criterion was not located. The company may maintain relevant practices or controls that are not publicly disclosed.

By dimension

Knowledge & context
50%
Agents & automation
44%
Model & infrastructure
25%
Data & AI security
33%
Organisation
44%
Economics & outcomes
25%
Business-model exposure
44%

Each dimension is the share of available points earned on the questions that could be scored from public evidence. 24 of 35 questions were scoreable; the remainder are outside the public-evidence instrument.

Evidence located

Questions on which the reviewed public sources contained disclosure meeting at least the level-2 anchor of the published rubric:

Level 3 — instances, or a disclosed number linked to a named system

  • AI deployed across functions
  • AI leadership and organisation

Level 2 — disclosed; not quantified or independently verified

  • named AI platform or knowledge substrate
  • internal AI tooling in use
  • guardrail and evaluation documentation
  • canonical data platform
  • AI talent or training figures
  • position on agentic or AI-mediated exposure
  • product that could not exist before AI, with volumes
  • leadership commitment and strategic response

Level descriptions are those of the published rubric. The evidence annexure sent to the company lists the specific documents and passages relied on for each question.

Where disclosure meeting the criterion was not located

In the public sources listed below, reviewed through 30 August 2026, we did not locate disclosure sufficient to satisfy the Index's published criterion for the following. The company may maintain relevant practices or controls that are not publicly disclosed.

  • production AI autonomy
  • orchestration or integration platform
  • model strategy or vendor architecture
  • hosting or infrastructure posture
  • open or external build surface
  • evaluation and benchmarking practice
  • API or integration surface
  • AI governance posture
  • role redesign around AI
  • AI-specific investment
  • AI attribution to reported economics
  • AI-attributed operational rate (a single statement of intent or unquantified claim was located and is cited in the annexure)
  • improvement trail and versioning (a single statement of intent or unquantified claim was located and is cited in the annexure)
  • AI-native monetisation

Sources reviewed

Raw /P total: 38.1 / 100; Ceilings: None triggered. D6 computes to exactly 25.0%, at the Outcome threshold rather than below it — the fifth such instance in; Band: AI Assisted (21–40), boundary marker (A8) — honest range ~36–42 crosses the AI Integrated line; Confidence: Grade B — 5 of 8 signal categories (no AI-specific talent evidence; no governance; no velocity trail); Financials (E1 provider pair): FY26 network gross revenue ₹10,538 crore (+16%); operating EBITDA ₹2,638 crore; PAT ₹1,631 crore; net debt/EBITDA below

Archive references

SourceOriginalArchiveCaptured
CMD interview cited as evidenceoriginalarchived copy2026-09-08

Exchange filings and reports relied on:

  • integrated annual report fy2025-26; integrated annual report; annual report — exchange archive
  • Q1–Q4 FY26 results / presentations — exchange archive
  • AI / platform / product page(s) — maxcare.ai
  • CMD interview cited as evidence

All sources archived at scoring date; the complete source archive register is available on request via corrections@thecompounding.company. Short quotations, where used, are attributed and used for the purpose of review. Right-of-reply notice sent 10 September 2026 to the Company Secretary, Investor Relations, registered office, corporate communications and legal function. Company response: none received as at publication. No response is characterised as agreement or endorsement.

This assessment is based exclusively on public information available during the stated evidence window. It does not assess undisclosed internal systems or practices. Scores and bands are opinions produced by applying the published rubric to the cited factual record. Not investment advice. The Index is not affiliated with, endorsed by, or sponsored by any assessed company.

Corrections: material factual errors are corrected promptly and logged. See the corrections log and the methodology, including its removal policy.